HPLC Determination of Entecavir in Pure , Tablet Dosage Form and Spiked Plasma
暂无分享,去创建一个
F. Nasim | M. Ashraf | M. Iqbal | Jameel Rahman | S. Ejaz | M. Hayat | Hafiz Muhammad Nauman Shabbir
[1] J. Chen,et al. Bioequivalence Evaluation of 2 Tablet Formulations of Entecavir in Healthy Chinese Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study , 2012, Arzneimittelforschung/Drug Research.
[2] B. Chandu,et al. LC-ESI-MS/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[3] D. R. Nogueira,et al. Development and validation of a stability-indicating capillary zone electrophoretic method for the assessment of entecavir and its correlation with liquid chromatographic methods. , 2011, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.
[4] P. Subrahmanyam,et al. Novel Spectrophotometric Methods For The Determination Of Entecavir In Pharmaceutical Dosage Forms , 2011 .
[5] D. R. Nogueira,et al. Validation of a stability-indicating RP-HPLC method for the determination of entecavir in tablet dosage form. , 2010, Journal of AOAC International.
[6] J. Gale,et al. A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC-MS/MS. , 2009, Journal of pharmaceutical and biomedical analysis.
[7] H. Van Vlierberghe,et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.
[8] L. Corey,et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. , 2001, The Journal of infectious diseases.